Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
- Apoptosis
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 195514-63-7] Rimiducid

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-16046
Brand:	MCE
CAS:	195514-63-7

Overview

MDL	MFCD25976784
Molecular Weight	1411.63
Molecular Formula	C78H98N4O20
SMILES	COC1=CC=C(CC[C@@H](OC([C@@H]2CCCCN2C([C@@H](CC)C3=CC(OC)=C(OC)C(OC)=C3)=O)=O)C4=CC=CC(OCC(NCCNC(COC5=CC([C@@H](CCC6=CC=C(OC)C(OC)=C6)OC([C@@H]7CCCCN7C([C@H](C8=CC(OC)=C(OC)C(OC)=C8)CC)=O)=O)=CC=C5)=O)=O)=C4)C=C1OC

For research use only. We do not sell to patients.

21 Publications Citing Use of MCE

[1]Nat Biomed Eng. 2022 Jun 6.
[2]Nat Chem Biol. 2021 Dec 2.
[3]Nat Commun. 2022 Dec 6;13(1):7522.
[4]Nat Commun. 2021 Dec 8;12(1):7114.
[5]Nat Commun. 2020 Apr 2;11(1):1625.
[6]Nucleic Acids Res. 2020 Jan 10;48(1):e1.
[7]Genome Med. 2021 Oct 14;13(1):165.
[8]Am J Hum Genet. 2020 Jul 2;107(1):111-123.
[9]Stem Cells Transl Med. 2020 Nov;9(11):1378-1388.
[10]PLoS Pathog. 2021 Jul 16;17(7):e1009715.
[11]Mol Ther-Meth Clin D. 2021 Mar 5.
[12]Sci Rep. 2021 Jun 1;11(1):11407.
[13]Sci Rep. 2019 Mar 6;9(1):3630.
[14]Int Immunopharmacol. 2020 Nov;88:106860.
[15]Patent. US20220177911A1.
[16]bioRxiv. January 06, 2022.
[17]Patent. US20210260125A1.
[18]University of Minnesota. 2021 Jul.
[19]Patent. US20200095604A1
[20]Patent. US20190271005A1.
[21]Patent. US20180155717A1.

Summary

Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis .

IC50 & Target

EC50: 0.1 nM (FKBP, in HT1080 cells) ^[1]
Fas receptor ^[1]

In Vitro

The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC ₅₀ of ≈0.1 nM ^[1] . Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC ₅₀ is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum human GH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02849886	Centre Hospitalier Universitaire de Besancon\|Etablissement Français du Sang\|Bellicum Pharmaceuticals	Graft Versus Host Disease\|Hematological Malignancies	April 10, 2019	Phase 1\|Phase 2
NCT03741127	Poseida Therapeutics, Inc.\|California Institute for Regenerative Medicine (CIRM)	Multiple Myeloma	October 29, 2018	Phase 1
NCT02107963	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Sarcoma\|Osteosarcoma\|Neuroblastoma\|Melanoma	February 28, 2014	Phase 1
NCT02744287	Bellicum Pharmaceuticals	Metastatic Castration-resistant Prostate Cancer\|Metastatic Prostate Cancer	November 2016	Phase 1\|Phase 2
NCT04249947	Poseida Therapeutics, Inc.	Prostatic Neoplasms, Castration-Resistant\|Neoplasms by Histologic Type\|Neoplasms, Prostate\|Prostate Cancer\|Metastatic Castration-resistant Prostate Cancer\|Neoplasms\|Prostatic Neoplasms\|Genital Neoplasms, Male\|Urogenital Neoplasms\|Neoplasms by Site\|Prostatic Disease\|Salivary Gland Cancer\|Salivary Gland Tumor\|Adenoid Cystic Carcinoma\|Salivary Duct Carcinoma\|Mucoepidermoid Carcinoma\|Acinic Cell Tumor	February 28, 2020	Phase 1
NCT03016377	UNC Lineberger Comprehensive Cancer Center\|Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Immune System Diseases\|Immunoproliferative Disorders	March 22, 2012	Phase 1\|Phase 2
NCT01823978	Bellicum Pharmaceuticals	Castrate Resistent Prostate Cancer	April 2013	Phase 1
NCT03056339	M.D. Anderson Cancer Center	B-Lymphoid Malignancies\|Acute Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia\|Non-hodgkin Lymphoma	June 21, 2017	Phase 1\|Phase 2
NCT03301168	Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Leukemia, Acute Myeloid (AML), Child\|Lymphoma, Non-Hodgkin\|Myelodysplastic Syndromes\|Primary Immune Deficiency Disorder\|Osteopetrosis\|Cytopenia\|Hemoglobinopathy in Children\|Anemia, Aplastic	April 2014	Phase 1\|Phase 2
NCT02477878	Bellicum Pharmaceuticals	Leukemia\|Myelodysplastic Syndromes\|Lymphoma\|Multiple Myeloma\|Hematologic Neoplasms	July 2016	Phase 1
NCT01744223	Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Acute Myelogenous Leukemia\|Lymphoma\|Myelodysplastic Syndromes	March 2013	Phase 1\|Phase 2
NCT03958656	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Myeloma-Multiple\|Myeloma, Plasma-Cell	June 13, 2019	Phase 1
NCT03459170	Bellicum Pharmaceuticals	Hematologic Malignancy	February 1, 2018	Phase 1
NCT01875237	M.D. Anderson Cancer Center\|Bellicum Pharmaceuticals	Leukemia\|Myeloma\|Myeloproliferative Diseases	December 27, 2013	Phase 1\|Phase 2
NCT02743611	Bellicum Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Uveal Melanoma	April 14, 2017	Phase 1\|Phase 2
NCT03288493	Poseida Therapeutics, Inc.\|California Institute for Regenerative Medicine (CIRM)	Multiple Myeloma	September 20, 2017	Phase 1\|Phase 2
NCT02065869	Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Leukemia, Acute Myeloid (AML), Child\|Lymphoma, Non-Hodgkin\|Myelodysplastic Syndrome\|Primary Immunodeficiency\|Anemia, Aplastic\|Osteopetrosis\|Hemoglobinopathies\|Cytopenia\|Fanconi Anemia\|Diamond Blackfan Anemia\|Thalassemia\|Anemia, Sickle Cell	April 2014	Phase 2
NCT02231710	Bellicum Pharmaceuticals	Primary Immune Deficiency Disorders\|Hemophagocytic Lymphohistiocytosis\|Inherited Bone Marrow Failure Syndrome\|Hemoglobinopathies\|Metabolic Disorders	February 2015	Phase 1
NCT02487459	Bellicum Pharmaceuticals	Hematologic Malignancies	July 2016	Phase 1
NCT03594162	UNC Lineberger Comprehensive Cancer Center\|Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Immune System Diseases\|Immunoproliferative Disorders
NCT02792114	Memorial Sloan Kettering Cancer Center\|United States Department of Defense	Breast Cancer\|Metastatic HER2-negative Breast	June 2016	Phase 1
NCT03696784	UNC Lineberger Comprehensive Cancer Center\|Bellicum Pharmaceuticals\|The V Foundation	Lymphoma\|Lymphoma, B-Cell\|Immune System Diseases\|Immunoproliferative Disorders\|Lymphatic Diseases	March 12, 2019	Phase 1
NCT01494103	Baylor College of Medicine\|The Methodist Hospital Research Institute\|Center for Cell and Gene Therapy, Baylor College of Medicine	Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Chronic Myelogenous Leukemia\|Non Hodgkin Lymphoma\|Hemophagocytic Lymphohistiocytosis\|Familial Hemophagocytic Lymphohistiocytosis\|Hemophagocytic Syndrome\|Epstein Barr Virus Infection\|X-linked Lymphoproliferative Disease	November 2011	Phase 1
NCT03699475	Bellicum Pharmaceuticals	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	December 27, 2018	Phase 2\|Phase 3
NCT02786485	Bellicum Pharmaceuticals	Leukemia\|Myelodysplastic Syndromes\|Lymphomas\|Multiple Myeloma\|Other High-risk Hematological Malignancies	May 2016	Phase 1
NCT04960579	Poseida Therapeutics, Inc.	Multiple Myeloma	May 5, 2022	Phase 1
NCT03807063	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)\|Bellicum Pharmaceuticals	Acute Bilineal Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Myeloproliferative Neoplasm\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome	January 2, 2020	Phase 1
NCT03733249	Bellicum Pharmaceuticals	Acute Lymphoblastic Leukemia\|Leukemia, Acute Myeloid (AML), Child\|Lymphoma, Non-Hodgkin\|Myelodysplastic Syndromes\|Primary Immunodeficiency\|Anemia, Aplastic\|Hemoglobinopathies\|Cytopenia\|Fanconi Anemia\|Diamond Blackfan Anemia\|Thalassemia\|Anemia, Sickle Cell	January 2017	Phase 1\|Phase 2
NCT00868595	Bellicum Pharmaceuticals\|M.D. Anderson Cancer Center\|The University of Texas Health Science Center, Houston\|Memorial Hermann Hospital\|Baylor College of Medicine	Castrate Resistant Prostate Cancer (CRPC)	April 2009	Phase 1
NCT03639844	Bellicum Pharmaceuticals	Hurler Syndrome\|Inherited Metabolic Disorder\|Lysosomal Storage Disorder\|Metachromatic Leukodystrophy\|Inborn Errors of Metabolism
NCT05239143	Poseida Therapeutics, Inc.	Breast Cancer\|Ovarian Cancer\|Non Small Cell Lung Cancer\|Colorectal Cancer\|Pancreatic Cancer\|Renal Cell Carcinoma\|Nasopharyngeal Cancer\|Head and Neck Squamous Cell Carcinoma\|Gastric Cancer	February 15, 2022	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 35.42 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7084 mL	3.5420 mL	7.0840 mL
5 mM	0.1417 mL	0.7084 mL	1.4168 mL
10 mM	0.0708 mL	0.3542 mL	0.7084 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (1.77 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Clackson T, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42.
[2] Thomis DC, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001 Mar 1;97(5):1249-57.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart